Identical Brains Studios IPO subscribed 199 times on Day 3. Check GMP and other details
Team Finance Saathi
20/Dec/2024

What's covered under the Article:
- Identical Brains Studios IPO opens December 18-20, 2024, with a subscription status of 199 times.
- IPO GMP shows strong listing potential, with expected gains of ₹28 (51.85%).
- How to check allotment status and key takeaways for potential investors.
Identical Brains Studios IPO: Overview and Details Identical Brains Studios, a leader in providing computer-generated visual effects (VFX) services, is set to launch its Book Built Issue IPO amounting to ₹19.95 Crores. The IPO will consist entirely of a Fresh Issue of 36.94 Lakh shares, with a price band of ₹51 to ₹54 per equity share. The market capitalization at the upper issue price will stand at ₹75.74 Crores.
The subscription period for the IPO runs from December 18 to December 20, 2024, with the allotment date expected on December 23, 2024. The shares will be listed on the NSE SME with a tentative listing date of December 26, 2024.
IPO Pricing and Investment Details The lot size for the IPO is 2,000 shares, requiring a minimum investment of ₹1,08,000 for retail investors. High-Net-Worth Individuals (HNIs) need to apply for a minimum of 4,000 shares, totaling ₹2,16,000. Socradamus Capital Private Limited is the book-running lead manager, while Bigshare Services Private Limited is the registrar for the issue. Rikhav Securities Limited is the market maker for the IPO.
Identical Brains Studios IPO Grey Market Premium (GMP) The Grey Market Premium (GMP) for the Identical Brains Studios IPO stands at ₹28, representing a potential listing gain of 51.85%. This suggests a strong demand for the shares, though GMP should be considered informational, as actual price discovery occurs only after the listing on the stock exchange.
Here’s a glimpse of the GMP trend:
- 17 December 2024: ₹28 (51.85%) increase in expected listing price
- 16 December 2024: ₹11 (20.37%) increase in expected listing price
Live Subscription Status As of 12:00 PM on December 20, 2024, the Identical Brains Studios IPO is 199 times subscribed on its final day of the subscription period, indicating high demand. You can check the live subscription status on the NSE website for real-time updates.
Anchor Investors and Fundraising Identical Brains Studios has raised ₹5.65 Crores from Anchor Investors at ₹54 per share. These investors have been allocated 10,48,000 equity shares, signaling strong institutional interest.
IPO Allotment Status Guide The allotment date for the Identical Brains Studios IPO is December 23, 2024, and investors can check their allotment status through the registrar’s website. Here’s how:
- Visit the IPO allotment status page on the registrar’s website.
- Select Identical Brains Studios Limited IPO from the dropdown list.
- Enter your application number, PAN, or DP Client ID.
- Submit to check the status.
Identical Brains Studios IPO Review Identical Brains Studios, under the leadership of Raghvendra Rai, has established itself as a key player in the VFX industry. The company's proprietary workflow and technology deliver high-quality VFX services for films, TV series, documentaries, and commercials, with clients including leading Bollywood studios.
The company's financial performance shows steady growth:
- Revenues for FY 2024: ₹1,139.49 Lakh
- EBITDA for FY 2024: ₹433.14 Lakh
- Profit After Tax (PAT) for FY 2024: ₹240.54 Lakh
Valuation and Financial Metrics:
- The Pre-Issue P/E ratio is 10.42x, while the Post-Issue P/E ratio is 14.17x, which is favorable compared to the industry P/E ratio of 15x.
- The Return on Capital Employed (ROCE) for FY 2024 stands at a robust 103.52%, and the Return on Equity (RoE) for FY 2024 is 71.66%.
Given these metrics and the strong IPO demand, the Identical Brains Studios IPO is fairly priced and presents a good investment opportunity for risky investors aiming for listing gains.
Investment Opportunity If you're looking to invest in a high-growth company in the VFX industry, the Identical Brains Studios IPO offers an attractive opportunity. With strong financial performance and a 51.85% GMP, it holds the potential for good listing gains upon its listing on the NSE SME.